Show simple item record

dc.contributor.authorAtmar, Robert L
dc.contributor.authorLyke, Kirsten E
dc.contributor.authorDeming, Meagan E
dc.contributor.authorJackson, Lisa A
dc.contributor.authorBranche, Angela R
dc.contributor.authorEl Sahly, Hana M
dc.contributor.authorRostad, Christina A
dc.contributor.authorMartin, Judith M
dc.contributor.authorJohnston, Christine
dc.contributor.authorRupp, Richard E
dc.contributor.authorMulligan, Mark J
dc.contributor.authorBrady, Rebecca C
dc.contributor.authorFrenck, Robert W
dc.contributor.authorBäcker, Martín
dc.contributor.authorKottkamp, Angelica C
dc.contributor.authorBabu, Tara M
dc.contributor.authorRajakumar, Kumaravel
dc.contributor.authorEdupuganti, Srilatha
dc.contributor.authorDobrzynski, David
dc.contributor.authorColer, Rhea N
dc.contributor.authorPosavad, Christine M
dc.contributor.authorArcher, Janet I
dc.contributor.authorCrandon, Sonja
dc.contributor.authorNayak, Seema U
dc.contributor.authorSzydlo, Daniel
dc.contributor.authorZemanek, Jillian A
dc.contributor.authorDominguez Islas, Clara P
dc.contributor.authorBrown, Elizabeth R
dc.contributor.authorSuthar, Mehul S
dc.contributor.authorMcElrath, M Juliana
dc.contributor.authorMcDermott, Adrian B
dc.contributor.authorO'Connell, Sarah E
dc.contributor.authorMontefiori, David C
dc.contributor.authorEaton, Amanda
dc.contributor.authorNeuzil, Kathleen M
dc.contributor.authorStephens, David S
dc.contributor.authorRoberts, Paul C
dc.contributor.authorBeigel, John H
dc.date.accessioned2022-02-17T16:06:51Z
dc.date.available2022-02-17T16:06:51Z
dc.date.issued2022-01-26
dc.identifier.urihttp://hdl.handle.net/10713/18021
dc.description.abstractIn this phase 1-2, open-label clinical trial conducted at 10 sites in the United States, adults who had completed a Covid-19 vaccine regimen at least 12 weeks earlier and had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received a booster injection with one of three vaccines: mRNA-1273 (Moderna) at a dose of 100 μg, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×1010 virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 μg. The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29.en_US
dc.description.urihttps://doi.org/10.1056/NEJMoa2116414en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35081293/en_US
dc.language.isoenen_US
dc.publisherMassachusetts Medical Societyen_US
dc.relation.ispartofNew England Journal of Medicineen_US
dc.rightsCopyright © 2022 Massachusetts Medical Society.en_US
dc.titleHomologous and Heterologous Covid-19 Booster Vaccinations.en_US
dc.typeArticleen_US
dc.identifier.doi10.1056/NEJMoa2116414
dc.identifier.pmid35081293
dc.source.journaltitleThe New England journal of medicine
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record